DaeWoong Pharmaceutical Announces IDMC Recommendation to Continue Global Phase 2 Clinical Trial for Bersiporocin
DaeWoong Pharmaceutical Co., Ltd. announced that its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), has received a recommendation to continue its global Phase 2 clinical trial following a positive safety review by the third Independent Data Monitoring Committee (IDMC).
The IDMC evaluated interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation. To date, 94 participants have been enrolled, representing approximately 92% of the target population (102 patients).
The study is progressing as planned.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study
Author's summary: DaeWoong Pharmaceutical continues global Phase 2 clinical trial for Bersiporocin.